ClinicalTrials.gg
CompletedNCT02621385Updated Apr 27, 2016

Study to Assess the Effect of Multiple Doses of Tradipitant on CYP3A4 Using Midazolam as a Substrate in Healthy Subjects

A Phase 1 interventional study of tradipitant and Midazolam in Healthy Volunteers, sponsored by Vanda Pharmaceuticals. Completed at 1 site in Switzerland. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-04-27.

Sponsored by Vanda Pharmaceuticals · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This study is designed to evaluate the potential effect of administration of tradipitant on CYP3A4 using midazolam pharmacokinetics as markers.

The study will also further characterize the pharmacokinetics of tradipitant.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Vanda Pharmaceuticals is the lead sponsor of 82 studies on the registry; 17 are open to participants now.

Of its 33 completed or terminated interventional studies of FDA-regulated products, 22 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Ability and acceptance to provide written ;
  2. Subjects must be males or females between 18 and 55 years of age, inclusive;
  3. Female subjects of must be non-pregnant and non-lactating and have a negative serum or urine pregnancy test at the Screening visit and at Check-in (Days -1) and agree not to attempt to become pregnant during the course of the study. Female subjects of childbearing potential (including peri-menopausal women who have had a menstrual bleeding within 1 year) must be using appropriate (e.g. intrauterine device [IUD], diaphragm or condom with spermicidal jelly or foam or cervical cap) for a period of 35 days before the first dosing, for the duration of the study, and recommended to use it for one month after the last dose. Women are considered to be not of childbearing potential if they have been surgically sterilized (physician-documented hysterectomy or tubal ligation);

    a. Note: Women are not permitted to use hormonal methods of birth control (e.g. oral contraceptives, hormonal intrauterine device [IUD], patch and ) and must use another acceptable method of birth control during the study and recommended to use it for one month after the last dose. Women currently taking oral contraceptives will be required to discontinue their regimen at least two weeks prior to first dosing.

  4. Subjects with (BMI) of ≥18 and ≤33kg/m2 (BMI = weight (kg)/ [height (m)]2);
  5. Vital signs (after 3 minutes resting in sitting position) which are within the ranges shown below:

    1. Body temperature between 35.0-37.5 °C;
    2. Systolic blood pressure between 90-150 mmHg;
    3. Diastolic blood pressure between 50-95 mmHg;
    4. Pulse rate between 50-100 beats per minute
  6. Willing and able to comply with study requirements;
  7. Subjects must be in good health as determined by past medical history, physical examination, , clinical laboratory tests and urinalysis;

Exclusion criteria

Exclusion Criteria:

  1. History of recent (within six months) drug or alcohol abuse as defined in DSM IV, Diagnostic Criteria for Drug and Alcohol Abuse or evidence of such abuse as indicated by the laboratory assays conducted during the Screening visit or at Check-in;
  2. Any major surgery within three months of Day 1 or any minor surgery within one month;
  3. Donation or loss of 400 mL or more of blood within 3 months prior to the Baseline Visit;
  4. History or current evidence of cardiovascular, hepatic, hematopoietic, renal, gastrointestinal or metabolic dysfunction judged by the Investigator to be ;
  5. Any condition requiring the regular use of medication;
  6. History of intolerance and/or to drugs including midazolam, tradipitant, or a medications similar to tradipitant and its accompanying within the past two months prior to Day 1;
  7. History (including family history) or current evidence of congenital long syndrome or known acquired QT interval prolongation;
  8. Subjects who are currently considered at suicide risk, any subject who has ever made a suicide attempt, or those who are currently demonstrating active (within the past 6 months) suicidal ideation as deemed by the Columbia Suicide Severity Rating Scale (C- SSRS);
  9. History of liver disease and/or positive for one or more of the following serological results:

    1. a positive antibody test (anti-HCV)
    2. a positive (ELISA and Western-to confirm positive finding) test result c. positive surface antigen (HBsAg)
  10. Treatment with any drug known to cause major organ system toxicity (e.g., chloramphenicol or tamoxifen) during the 60 days preceding Day 1;
  11. Elevated (> 2 times the ) liver function tests (i.e.

    (AST [SGOT]), alanine aminotransferase (ALT [SGPT]), and total );

  12. Inability to be venipunctured and/or tolerate venous access;
  13. Subjects who have used tobacco products 3 months prior to dosing. Tobacco users will be defined as any subject who reports cigarette, cigar, tobacco, nicotine gum, nicotine patch or electronic cigarette use;
  14. Consumption of >1 drink/day of alcohol for females and >2 drinks/day for males, defined according to the USDA Dietary Guidelines 2010 ;
  15. Consumption of >5 cups coffee/tea/day;
  16. Participation in the evaluation of any product for 3 months before this study. The 3-month interval is calculated as the time between the first calendar day of the month that follows the last visit of the previous study and the first day of the present study;
  17. Use of prescription or OTC medications, including herbal products (e.g., St. John's Wort) within 2 weeks of Day 1;
  18. Use of any food or beverage containing alcohol, grapefruit or grapefruit juice, apple or orange juice, vegetables from the mustard green family (e.g. kale, broccoli, watercress, collard greens, kohlrabi, Brussels sprouts, mustard) and charbroiled meat within 1 week before Day 1;
  19. Abnormal diets (\<1600 or >3500 kcal/day), substantial changes in eating habits in the 4 weeks before this study, or vegetarians;
  20. Participation in a previous LY686017 or VLY-686/tradipitant trial;
  21. Anyone affiliated with the site or sponsor and/or anyone who may consent under duress;
  22. Any other sound medical reason as determined by the clinical Investigator.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Tradipitant

    One dose of midazolam followed by tradipitant dosing for days 3-16. Midazolam is also given on day 16

    Drug: tradipitant · Drug: Midazolam

Interventions

06

What researchers measure

Primary outcomes

  1. Midazolam Area Under the Curve (AUC)

    Time frame: Pre-dose,0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36, 48, and 72 hours

  2. Midazolam time to maximal plasma concentration (Tmax)

    Time frame: Pre-dose,0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36, 48, and 72 hours

  3. Midazolam maximal plasma concentration (Cmax)

    Time frame: Pre-dose,0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36, 48, and 72 hours

Secondary outcomes

  1. α-hydroxymidazolam area under the curve(AUC)

    Time frame: pre-dose, and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours

  2. α-hydroxymidazolam time to maximal plasma concentration (Tmax)

    Time frame: pre-dose, and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24

  3. α-hydroxymidazolam maximal plasma concentration (Cmax)

    Time frame: pre-dose, and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24

  4. Tradipitant and tradipitant metabolites area under the curve (AUC)

    Time frame: pre-dose, and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24

  5. Tradipitant and tradipitant metabolites time to maximal plasma concentration (Tmax)

    Time frame: pre-dose, and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24

  6. Tradipitant and tradipitant metabolites maximal plasma concentration (Cmax)

    Time frame: pre-dose, and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24

  7. Safety of multiple oral doses of tradipitant alone and in combination with midazolam by spontaneous reporting of AEs measured by events related to treatment.

    Time frame: 19 days

  8. Safety of multiple oral doses of tradipitant alone and in combination with midazolam by number of participants with abnormal laboratory values

    Time frame: 19 days

  9. Safety of multiple oral doses of tradipitant alone and in combination with midazolam by number of participants with abnormal ECG values

    Time frame: 19 days

  10. Safety of multiple oral doses of tradipitant alone and in combination with midazolam by number of participants with abnormal vital signs

    Time frame: 19 days

  11. • The Columbia Suicide Severity Rating Scale will be used to assess suicidal behavior and ideation

    Time frame: Baseline, Day 10, Day 19

07

Study locations

1 site
  • Vanda Investigational Site
    Arzo, 6864, Switzerland
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2015 and a primary completion of Feb 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2015
First posted
Dec 3, 2015
Start
Nov 2015
Primary completionActual
Feb 2016
Last update
Apr 27, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 27, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02621385
Collaborators
Cross Research S.A.
Responsible party
Sponsor
First posted
Dec 3, 2015
Start date
Nov 2015
Primary completion
Feb 2016
Last update
Apr 27, 2016

Study contacts

Milko Radicioni, MD
principal investigator · CROSS Research SA

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tradipitant · Midazolam

Start the discussion